|
Assessment of Attentional Functioning in Children with HIV-1 Infection Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Assessment of Attentional Functioning in Children with HIV-1 Infection conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Assessment of Attentional Functioning in Children with HIV-1 Infection Clinical research trials and Assessment of Attentional Functioning in Children with HIV-1 Infection medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Assessment of Attentional Functioning in Children with HIV-1 Infection. Assessment of Attentional Functioning in Children with HIV-1 Infection Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Assessment of Attentional Functioning in Children with HIV-1 Infection clinical trial. Subjects typically recieve the finest healthcare available for their Assessment of Attentional Functioning in Children with HIV-1 Infection condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Assessment of Attentional Functioning in Children with HIV-1 Infection  Assessment of Attentional Functioning in Children with HIV-1 Infection
Assessment of Attentional Functioning in Children with HIV-1 Infection
For Condition: Attention Deficit Disorder with Hyperactivity,HIV Infections,Paralysis
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Children with symptomatic HIV-1 (Human Immunodeficiency Virus) infection are at increased risk for developing severely disabling neurological and neuropsychological deficits. HIV-1 related CNS (Central Nervous System) disease is a clinical syndrome, manifested by varying and sometimes discordant degrees of cognitive, motor and behavioral impairment. A continuum of clinical presentations attributed to the effects of HIV-1 infection on the CNS, ranging from apparently normal development, decreases in the rate of new learning to the loss of acquired skills have been observed. Two domains of psychological functioning appear most susceptible to the effects of HIV infection on the central nervous system in children: expressive behavior and attentional processes (Brouwers, et al, 1994). Attention deficits have been documented as a relative weakness on the "freedom from distractibility" subclass of IQ tests (Brouwers et al, 1989) and on behavior assessment (Moss et al, 1994). Attention, however, has many subcomponents such as focused attention, divided attention, vigilance, etc. Direct assessment of attentional functioning using reaction time has not yet been conducted and questions whether attentional components are differentially affected by the virus have not been addressed. The proposed study would assess different components of attentional functioning in children with HIV-1 disease. A quantitative and systematic method is developed that could complement the existing standardized instruments used for measuring attention and neurocognitive function in this population. Simple alerted visual reaction time will be measured with varying preparatory intervals, a two-choice reaction time in a go/no-go paradigm will be administered, and a continuous performance, divided reaction time test and an object decision task will be given. Performance on these measures will also be related to measures of brain structure and stage of HIV-1 disease.
Details: Children with symptomatic HIV-1 (Human Immunodeficiency Virus) infection are at increased risk for developing severely disabling neurological and neuropsychological deficits. HIV-1 related CNS (Central Nervous System) disease is a clinical syndrome, manifested by varying and sometimes discordant degrees of cognitive, motor and behavioral impairment. A continuum of clinical presentations attributed to the effects of HIV-1 infection on the CNS, ranging from apparently normal development, decreases in the rate of new learning to the loss of acquired skills have been observed. Two domains of psychological functioning appear most susceptible to the effects of HIV infection on the central nervous system in children: expressive behavior and attentional processes (Brouwers, et al, 1994). Attention deficits have been documented as a relative weakness on the "freedom from distractibility" subclass of IQ tests (Brouwers et al, 1989) and on behavior assessment (Moss et al, 1994). Attention, however, has many subcomponents such as focused attention, divided attention, vigilance, etc. Direct assessment of attentional functioning using reaction time has not yet been conducted and questions whether attentional components are differentially affected by the virus have not been addressed. The proposed study would assess different components of attentional functioning in children with HIV-1 disease. A quantitative and systematic method is developed that could complement the existing standardized instruments used for measuring attention and neurocognitive function in this population. Simple alerted visual reaction time will be measured with varying preparatory intervals, a two-choice reaction time in a go/no-go paradigm will be administered, and a continuous performance, divided reaction time test and an object decision task will be given. Performance on these measures will also be related to measures of brain structure and stage of HIV-1 disease.
Eligibility:
Study Type: Observational, Screening
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Children and adolescents with HIV infection ages 5-18. Have to be on another treatment protocol at the Division of Clinical Sciences, NCI. No children with non-HIV associated CNS compromise, such as for example resulting from head trauma, or genetic factors. No children with uncorrectable (20/20) vision.
Total Enrollment: 90
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960030; 96-C-0030
Study Start Date: December 29, 1995
Record last reviewed: November 1, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001497
Other Paralysis Studies:
1. Assessment of Attentional Functioning in Children with HIV-1 Infection
2. The Early Reversibility of Rocuronium After Different Doses of Neostigmine
3. Motor Recovery in Recent Stroke Patients Treated with Amphetamine and Physical Therapy
Related Studies:
Other Paralysis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Assessment of Attentional Functioning in Children with HIV-1 Infection
|
|
|
|
|
|
|
|
